Systematic review and meta-analysis of the possible association between pharmacological gastric acid suppression and spontaneous bacterial peritonitis

European Journal of Gastroenterology and Hepatology

Volumn 27, Issue 11, 2015, Pages 1327-1336

  Khan, Muhammad Ali ^a,b   Kamal, Sehrish ^a,b   Khan, Sobia ^b   Lee, Wade M ^c   Howden, Colin W ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b MEDICAL COLLEGE OF OHIO   (United States)

^c UNIVERSITY OF TOLEDO   (United States)

Author keywords

Ascites; Cirrhosis; H2 receptor antagonists; Proton pump inhibitors; Spontaneous bacterial peritonitis

Indexed keywords

HISTAMINE H2 RECEPTOR; PROTON PUMP INHIBITOR; HISTAMINE H2 RECEPTOR ANTAGONIST;

BACTERIAL PERITONITIS; DISEASE ASSOCIATION; GASTRIC ACID SUPPRESSION; HUMAN; LIVER CIRRHOSIS; PHARMACEUTICAL CARE; PRIORITY JOURNAL; REVIEW; STOMACH ACID SECRETION; SYSTEMATIC REVIEW; BACTERIAL INFECTIONS; COMPLICATION; META ANALYSIS; MICROBIOLOGY; PERITONITIS; SECRETION (PROCESS); STOMACH ACID;

BACTERIAL INFECTIONS; GASTRIC ACID; HISTAMINE H2 ANTAGONISTS; HUMANS; LIVER CIRRHOSIS; PERITONITIS; PROTON PUMP INHIBITORS;

EID: 84942745875     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000448     Document Type: Review

References (53)

1. Wolfe MM, Soll AH. The physiology of gastric acid secretion. N Engl J Med 1988; 319:1707-1715.
2. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 2013; 108:308-328; quiz 329.
3. Poynard T, Lemaire M, Agostini H. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. Eur J Gastroenterol Hepatol 1995; 7:661-665.
4. Yachimski PS, Farrell EA, Hunt DP, Reid AE. Proton pump inhibitors for prophylaxis of nosocomial upper gastrointestinal tract bleeding: effect of standardized guidelines on prescribing practice. Arch Intern Med 2010; 170:779-783.
5. Cote GA, Howden CW. Potential adverse effects of proton pump inhibitors. Curr Gastroenterol Rep 2008; 10:208-214.
6. Corley DA, Kubo A, Zhao W, Quesenberry C. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology 2010; 139:93-101.
7. Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004; 292:1955-1960.
8. Prod'hom G, Leuenberger P, Koerfer J, Blum A, Chiolero R, Schaller MD, et al. Nosocomial pneumonia in mechanically ventilated patients receiving antacid, ranitidine, or sucralfate as prophylaxis for stress ulcer. A randomized controlled trial. Ann Intern Med 1994; 120:653-662.
9. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007; 102:2047-2056. quiz 57.
10. Deshpande A, Pasupuleti V, Thota P, Pant C, Mapara S, Hassan S, et al. Acid-suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: A meta-analysis. J Gastroenterol Hepatol 2013; 28:235-242.
11. Wiest R, Krag A, Gerbes A. Spontaneous bacterial peritonitis: recent guidelines and beyond. Gut 2012; 61:297-310.
12. Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis 2008; 28:26-42.
13. Bustamante J, Rimola A, Ventura PJ, Navasa M, Cirera I, Reggiardo V, Rodés J. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol 1999; 30:890-895.
14. Bauer TM, Steinbrückner B, Brinkmann FE, Ditzen AK, Schwacha H, Aponte JJ, et al. Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis. Am J Gastroenterol 2001; 96:2962-2967.
15. Pardo A, Bartolí R, Lorenzo-Zúñiga V, Planas R, Viñado B, Riba J, et al. Effect of cisapride on intestinal bacterial overgrowth and bacterial translocation in cirrhosis. Hepatology 2000; 31:858-863.
16. Sánchez E, Such J, Chiva MT, Soriano G, Llovet T, Mercè J, et al. Development of an experimental model of induced bacterial peritonitis in cirrhotic rats with or without ascites. Am J Gastroenterol 2007; 102:1230-1236.
17. Rabinovitz M, Gavaler JS, Kumar S, Kajani M, Van Thiel DH. Role of serum complement, immunoglobulins, and cell-mediated immune system in the pathogenesis of spontaneous bacterial peritonitis (SBP). Dig Dis Sci 1989; 34:1547-1552.
18. Trikudanathan G, Israel J, Cappa J, O'Sullivan DM. Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients - A systematic review and meta-analysis. Int J Clin Pract 2011; 65:674-678.
19. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283:2008-2012.
20. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available athttp://www.ohri.ca/programs/clinical-epidemiology/oxford.asp[Accessed 22 July 2014].
21. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso- Coello P, Schünemann HJ. GRADE Working Group. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336:924-926.
22. Higgins JPT, Green S. Interpreting results and drawing conclusions. Cochrane Handbook for Systematic Reviews of Interventions, version 5.0.1. Available at: handbook.cochrane.org/chapter-12/box12-8-a-cochrane-applicability-and-recommendations-methods.htm [Accessed 26 July 2015].
23. Davies HT, Crombie IK, Tavakoli M. When can odds ratios mislead? BMJ 1998; 316:989-991.
24. Taddio A, Pain T, Fassos FF, Boon H, Ilersich AL, Einarson TR. Quality of nonstructured and structured abstracts of original research articles in the British Medical Journal, the Canadian Medical Association Journal and the Journal of the American Medical Association. CMAJ 1994; 150:1611-1615.
25. Scherer RW, Langenberg P, von Elm E. Full publication of results initially presented in abstracts. Cochrane Database Syst Rev 2007; 2:MR000005.
26. Der Simonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-188.
27. Higgins JPT, Green S. Identifying and measuring heterogeneity. Cochrane Handbook for Systematic Reviews of Interventions, version 5.0.1. Available at: handbook.cochrane.org/chapter-9/9-5-2-identifying-and-measuring-heterogeneity.htm. [Accessed 26 July 2015].
28. Ratelle M, Perreault S, Villeneuve JP, Tremblay L. Association between proton pump inhibitor use and spontaneous bacterial peritonitis in cirrhotic patients with ascites. Can J Gastroenterol Hepatol 2014; 28:330-334.
29. Bajaj JS, Zadvornova Y, Heuman DM, Hafeezullah M, Hoffmann RG, Sanyal AJ, Saeian K. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am J Gastroenterol 2009; 104:1130-1134.
30. Campbell MS, Obstein K, Reddy KR, Yang YX. Association between proton pump inhibitor use and spontaneous bacterial peritonitis. Dig Dis Sci 2008; 53:394-398.
31. Goel GA, Deshpande A, Lopez R, Hall GS, van Duin D, Carey WD. Increased rate of spontaneous bacterial peritonitis among cirrhotic patients receiving pharmacologic acid suppression. Clin Gastroenterol Hepatol 2012; 10:422-427.
32. Choi EJ, Lee HJ, Kim KO, Lee SH, Eun JR, Jang BI, Kim TN. Association between acid suppressive therapy and spontaneous bacterial peritonitis in cirrhotic patients with ascites. Scand J Gastroenterol 2011; 46:616-620.
33. de Vos M, De Vroey B, Garcia BG, Roy C, Kidd F, Henrion J, Deltenre P. Role of proton pump inhibitors in the occurrence and the prognosis of spontaneous bacterial peritonitis in cirrhotic patients with ascites. Liver Int 2013; 33:1316-1323.
34. Min YW, Lim KS, Min BH, Gwak GY, Paik YH, Choi MS, et al. Proton pump inhibitor use significantly increases the risk of spontaneous bacterial peritonitis in 1965 patients with cirrhosis and ascites: A propensity score matched cohort study. Aliment Pharmacol Ther 2014; 40:695-704.
35. Mandorfer M, Bota S, Schwabl P, Bucsics T, Pfisterer N, Summereder C, et al. Proton pump inhibitor intake neither predisposes to spontaneous bacterial peritonitis or other infections nor increases mortality in patients with cirrhosis and ascites. PLoS One 2014; 9: e110503.
36. Terg R, Casciato P, Garbe C, Cartier M, Stieben T, Mendizabal M, et al. Proton pump inhibitor therapy does not increase the incidence of spontaneous bacterial peritonitis in cirrhosis: A multicenter prospective study. J Hepatol 2015; 62:1056-1060.
37. Kwon JH, Koh SJ, Kim W, Jung YJ, Kim JW, Kim BG, et al. Mortality associated with proton pump inhibitors in cirrhotic patients with spontaneous bacterial peritonitis. J Gastroenterol Hepatol 2014; 29:775-781.
38. Miura K, Tanaka A, Yamamoto T, Adachi M, Takikawa H. Proton pump inhibitor use is associated with spontaneous bacterial peritonitis in patients with liver cirrhosis. Intern Med 2014; 53:1037-1042.
39. van Vlerken LG, Huisman EJ, van Hoek B, Renooij W, de Rooij FW, Siersema PD, van Erpecum KJ. Bacterial infections in cirrhosis: role of proton pump inhibitors and intestinal permeability. Eur J Clin Invest 2012; 42:760-767.
40. Northup PG, Argo CL, Berg CL. Chronic proton pump inhibitor use is strongly associated with hepatorenal syndrome and spontaneous bacterial peritonitis in cirrhosis patients. Hepatology 2008; 48:325A.
41. Bulsiewicz WJ, Scherer JR, Feinglass JM, Howden CW, Flamm SL. 63 Proton Pump Inhibitor (PPI) use is independently associated with spontaneous bacterial peritonitis (SBP) in cirrhotics with ascites. Gastroenterology 2009; 136:A-11.
42. Casafont Morencos F, de las Heras Castaño G, Martín Ramos L, López Arias MJ, Ledesma F, Pons Romero F. Small bowel bacterial overgrowth in patients with alcoholic cirrhosis. Dig Dis Sci 1995; 40:1252-1256.
43. Choung RS, Ruff KC, Malhotra A, Herrick L, Locke GR 3rd, Harmsen WS, et al. Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture. Aliment Pharmacol Ther 2011; 33:1059-1067.
44. Compare D, Pica L, Rocco A, De Giorgi F, Cuomo R, Sarnelli G, et al. Effects of long-term PPI treatment on producing bowel symptoms and SIBO. Eur J Clin Invest 2011; 41:380-386.
45. Ratuapli SK, Ellington TG, O'Neill MT, Umar SB, Harris LA, Foxx- Orenstein AE, et al. Proton pump inhibitor therapy use does not predispose to small intestinal bacterial overgrowth. Am J Gastroenterol 2012; 107:730-735.
46. Hutchinson S, Logan R. The effect of long-term omeprazole on the glucose-hydrogen breath test in elderly patients. Age Ageing 1997; 26:87-89.
47. Thorens J, Froehlich F, Schwizer W, Saraga E, Bille J, Gyr K, et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: A prospective randomised double blind study. Gut 1996; 39:54-59.
48. Law D, Pimentel M. Proton pump inhibitor therapy does not affect hydrogen production on lactulose breath test in subjects with IBS. Dig Dis Sci 2010; 55:2302-2308.
49. Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2010; 8:504-508.
50. Zedtwitz-Liebenstein K, Wenisch C, Patruta S, Parschalk B, Daxböck F, Graninger W. Omeprazole treatment diminishes intra- And extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med 2002; 30:1118-1122.
51. Howden CW. PPIs and clopidogrel: The band plays on. Am J Gastroenterol 2010; 105:2438-2439.
52. Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010; 363:1909-1917.
53. Chen J, Yuan YC, Leontiadis GI, Howden CW. Recent safety concerns with proton pump inhibitors. J Clin Gastroenterol 2012; 46:93-114.